The global gene therapy market , categorized by vectors (non-viral, including oligonucleotides, and viral, comprising retroviral and adeno-associated vectors), indication (covering cancer, neurological, hepatological diseases, and Duchenne muscular dystrophy), and delivery method (in vivo and ex vivo), is poised for remarkable expansion. It is projected to reach a valuation of USD 17.2 billion by 2027, demonstrating substantial growth from USD 7.3 billion recorded in 2022. This growth trajectory is characterized by a robust compound annual growth rate (CAGR) of 18.6% during the forecast period spanning from 2022 to 2027.

Several key factors are driving the growth of the gene therapy market. Notably, the increasing incidence of cancer and neurological diseases worldwide has spurred demand for innovative therapeutic approaches. Additionally, the continuous approval of gene therapy products by regulatory bodies and the escalating investments in gene therapy research and development are fostering market expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

Browse in-depth TOC on "Gene Therapy Market”

165 – Tables

33 – Figures

159 – Pages

Key Market Players

The gene therapy market is consolidated, with three major players holding the dominant share of the market. In 2021, Biogen (US), Novartis AG (Switzerland), and Gilead Sciences, Inc. (US) were the leading players in the gene therapy market. Other major players in this market include Sarepta Therapeutics (US), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), AGC Biologics (Italy), Orchard Therapeutics plc. (UK), Sibiono (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US). The intensity of competitive rivalry in the gene therapy market is high.

Novartis AG (Switzerland) was the leading player in the gene therapy market. The company offers two gene therapy products—KYMRIAH and ZOLGENSMA. Globally, the company has strong distribution channels and a good brand image. As a result, KYMRIAH registered significant growth in 2018—KYMRIAH registered sales of USD 587 million in 2021, up 24% from 2020. ZOLGENSMA registered sales of USD 1,351 million in 2021, up 47% from 2020. Novartis has strong distribution channels in the US. As a result, in 2021, the company generated 32.6% of its total revenue from the US alone.

Biogen (US) is the second-leading player in the gene therapy market. However, the revenue of SPINRAZA is declining year on year. The decline in SPINRAZA revenue was primarily brought on by a decline in demand because of heightened competition in the US and Germany and a decline in pricing in the US and the RoW markets, which were only partially offset by an uptick in sales volumes in Latin America and some distributor markets.

Request Free Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962 

The non-viral vectors segment accounted for the largest share in the gene therapy market, by vector, during the forecast period.

Based on vectors, the gene therapy market is segmented into non-viral vectors and viral vectors. Non-viral vectors accounted for the larger market share in 2021. Less immunogenicity than viral vectors coupled with easier mass production of non-viral vectors are the major factors driving the growth of this segment.

The Neurological diseases segment accounted for the largest share of the indication segment in the gene therapy market in 2021.

Based on indication, the gene therapy market is segmented into neurological diseases, cancer, duchenne muscular dystrophy, hepatological diseases, and other indications. The neurological diseases segment accounted for the largest share of the gene therapy market in 2021. The largest share is attributed to growing burden of neurological diseases coupled with rising adoption of gene therapy for the treatment of neurological disorders.

The in vivo segment accounted for the larger share of the delivery method segment in the gene therapy market in 2021.

On the basis of delivery method, the gene therapy market is segmented into in vivo and ex vivo. In vivo segment accounted for the larger share in the gene therapy market as majority of the approved gene therapy products fall under in vivo delivery method.

North America is the largest region and Asia Pacific is the fastest-growing region of the gene therapy market in 2021.

Based on region, the gene therapy market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2021, North America dominated the market, followed by Europe. The significant government and private investments to develop advanced gene therapy products, the growing adoption rate of these products, and the presence of key market players in the region are responsible for the large share of North America in the gene therapy market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857962

Recent Developments:

  • In February 2022, Sarepta Therpeutics (US) announced a collaboration to use GenEdit’s NanoGalaxy platform and Sarepta’s gene editing technology to develop gene editing therapeutics to treat neuromuscular diseases.
  • In May 2022, Novartis AG (Switzerland) received FDA approval for KYMRIAH for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/gene-therapy-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp